SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Graphic drawing white background
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.
February 6, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Donald Trump signing an executive order
Drug pricing
TrumpRx Website Set To Launch Thursday Evening After Delay
The administration’s direct-to-consumer pharmaceutical sales platform will offer products from Eli Lilly, Pfizer, Novo Nordisk, Amgen and more at a discount, though the impact of such pricing remains to be seen.
February 5, 2026
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Bristol Myers Squibb office in California
Earnings
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake.
February 5, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Trend artwork 3D photo collage sketch image of young sad stressed lady with headache burnout deadline overloaded tired work in office.
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
 · 
5 min read
 · 
Dan Samorodnitsky
South San Francisco, CA, USA - Feb 23, 2024: Exterior view of AbbVie's research facility in South San Francisco. AbbVie is an American pharmaceutical company headquartered in North Chicago, Illinois.
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed execs for more details; Merck and Roche also released Q4 and full year earnings, with Eli Lilly, Novo Nordisk and others reporting Wednesday; REGENXBIO hits a regulatory snag ahead of its upcoming PDUFA; more.
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Earnings
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
In its 2025 full year and fourth-quarter earnings call, Merck executives touted the merits of recent deals and what CEO Robert Davis called “probably the broadest and widest pipeline we’ve had in years.”
February 3, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Drop of blood from puzzles in hands, as metaphor for donation and fight against cancer caused by leukocyte disease. People donate blood to help sick patients in need of plasma transfusions
Cancer
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.
January 30, 2026
 · 
4 min read
 · 
Dan Samorodnitsky
Composite photo collage of business people hands hold checkered flags success finish vote competition isolated on painted background.
Rare diseases
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
The discovery of a tumor in a patient who received REGENXBIO’s gene therapy for Hurler syndrome prompted the FDA to place a hold on that program along with the company’s Hunter syndrome program, which is awaiting an FDA decision on or before Feb. 8.
January 28, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
 · 
1 min read
 · 
Heather McKenzie
The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
The Westin St. Francis in San Francisco, home of the J.P. Morgan Healthcare Conference.
JPM
JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
January 27, 2026
 · 
6 min read
 · 
Annalee Armstrong
Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Johnson and Johnson sign
Earnings
J&J Aims for $100B in Sales, Puts Stelara Patent Cliff ‘in the Rearview Mirror’
Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.
January 21, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Industry Leader and Market Dominance of a Company
Business
JPM26: KalVista’s HAE Win Is a ‘Tale of Two Markets’
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
January 21, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Load More